Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response

Department of Psychiatry and Behavioral Sciences, Center on Pharmacogenomics, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Molecular Psychiatry (Impact Factor: 15.15). 09/2008; 13(8):800-12. DOI: 10.1038/mp.2008.59
Source: PubMed

ABSTRACT There are clinical parallels between the nature and course of depressive symptoms in major depressive disorder (MDD) and those of inflammatory disorders. However, the characterization of a possible immune system dysregulation in MDD has been challenging. Emerging data support the role of T-cell dysfunction. Here we report the association of MDD and antidepressant response to genes important in the modulation of the hypothalamic-pituitary-adrenal axis and immune functions in Mexican Americans with major depression. Specifically, single nucleotide polymorphisms (SNPs) in two genes critical for T-cell function are associated with susceptibility to MDD: PSMB4 (proteasome beta4 subunit), important for antigen processing, and TBX21 (T bet), critical for differentiation. Our analyses revealed a significant combined allele dose-effect: individuals who had one, two and three risk alleles were 2.3, 3.2 and 9.8 times more likely to have the diagnosis of MDD, respectively. We found associations of several SNPs and antidepressant response; those genes support the role of T cell (CD3E, PRKCH, PSMD9 and STAT3) and hypothalamic-pituitary-adrenal axis (UCN3) functions in treatment response. We also describe in MDD increased levels of CXCL10/IP-10, which decreased in response to antidepressants. This further suggests predominance of type 1 T-cell activity in MDD. T-cell function variations that we describe here may account for 47.8% of the attributable risk in Mexican Americans with moderate MDD. Immune function genes are highly variable; therefore, different genes might be implicated in distinct population groups.

Download full-text


Available from: Chuanhui Dong, Jun 29, 2014
  • Source
    • "r suggested to induce GR resistance and trigger the inflammatory cascade ( Miller et al . , 2002 ; Raison et al . , 2006 ; Cohen et al . , 2012 ) . From the genetic perspective , polymorphisms in the genes PSMB4 ( proteasome β4 subunit ) and TBX21 ( T bet ) that result in T - cell dysfunction , were reported to contribute to the pathology of MDD ( Wong et al . , 2008 ; Berk et al . , 2013 ) . A recent meta - analysis of 28 studies identified significant associations between depression and infections in Borna disease virus ( BDV ) , herpes simplex virus - 1 , varicella zoster virus , Epstein - Bar virus ( EBV ) , and Chlamydophila trachomatis . Results indicated that patients with depression are 3 . 2"
    [Show abstract] [Hide abstract]
    ABSTRACT: Major depressive disorder (MDD) is a mood disorder of multifactorial origin affecting millions of people worldwide. The alarming estimated rates of prevalence and relapse make it a global public health concern. Moreover, the current setback of available antidepressants in the clinical setting is discouraging. Therefore, efforts to eradicate depression should be directed towards understanding the pathomechanisms involved in the hope of finding cost-effective treatment alternatives. The pathophysiology of MDD comprises the breakdown of different pathways, including the hypothalamus-pituitary-adrenal (HPA) axis, the glutamatergic system, and monoaminergic neurotransmission, affecting cognition and emotional behavior. Inflammatory cytokines have been postulated to be the possible link and culprit in the disruption of these systems. In addition, evidence from different studies suggests that impairment of glial functions appears to be a major contributor as well. Thus, the intricate role between glia, namely microglia and astrocytes, and the central nervous system's (CNSs) immune response is briefly discussed, highlighting the kynurenine pathway as a pivotal player. Moreover, evaluations of different treatment strategies targeting the inflammatory response are considered. The immuno-modulatory properties of vitamin D receptor (VDR) suggest that vitamin D is an attractive and plausible candidate in spite of controversial findings. Further research investigating the role of VDR in mood disorders is warranted.
    Frontiers in Cellular Neuroscience 07/2015; 9:268. DOI:10.3389/fncel.2015.00268 · 4.18 Impact Factor
  • Source
    • "Neuropsychiatric disorders, such as depression and schizophrenia, are debilitating diseases with a high prevalence (Kessler et al., 2003). Among other factors, inflammation has emerged as a critical player in the pathophysiology of depression and many other neuropsychiatric disorders (Wong et al., 2008; Maes et al., 2009; Farooq et al., 2012). In the clinic, medical conditions involving systemic and/or central inflammatory events are closely correlated with clinical manifestations of mental illnesses (Dantzer et al., 2008, 2011; Kumar et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuroinflammatory disturbances have been closely associated with depression and many other neuropsychiatric diseases. Although targeting neuroinflammatory mediators with centrally-acting drugs has shown certain promise, its translation is faced with several challenges especially drug delivery and safety concerns. Here, we report that neuroinflammation-induced behavioral abnormality could be effectively attenuated with immunomodulatory agents that need not to gain brain penetration. In a rat model with intracerebral lipopolysaccharide (LPS) challenge, we validated that ginsenoside Rg1 (Rg1), a well-established anti-inflammatory agent, was unable to produce a direct action in the brain. Interestingly, peripherally-restricted Rg1 could effectively attenuate the weight loss, anorexic- and depressive-like behavior as well as neurochemical disturbances associated with central LPS challenge. Biochemical assay of neuroimmune mediators in the periphery revealed that Rg1 could mitigate the deregulation of the hypothalamic-pituitary-adrenal (HPA) axis and selectively blunt the increase in circulating interleukin (IL)-6 levels. Furthermore, these peripheral regulatory effects were accompanied by dampened microglial activation, mitigated expression of pro-inflammatory mediators and neurotoxic species in the central compartment. Taken together, our work suggested that targeting the peripheral immune system may serve as a novel therapeutic approach to neuroinflammation-induced neuropsychiatric disorders. Moreover, our findings provided the rationale for employing peripherally-active agents like Rg1 to combat mental disturbances.
    Neuroscience 10/2013; 256. DOI:10.1016/j.neuroscience.2013.10.023 · 3.33 Impact Factor
  • Source
    • "Author's personal copy sickness-like behaviour) (Kipnis et al. 2008; McAfoose and Baune 2009; Eyre and Baune 2012a, b). Given the links between the immune system and chronobiological processes in depression—the effect of AD and melatonin on the immune system—it is relevant to consider the role of AD chronotherapeutic agents on immune-circadian interaction (Wong et al. 2008; Antonioli et al. 2012; Haroon et al. 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The rising burden of unipolar depression along with its often related sleep disturbances, as well as increasing rates of sleep restriction in modern society, make the search for an extended understanding of the aetiology and pathophysiology of depression necessary. Accumulating evidence suggests an important role for the immune system in mediating disrupted neurobiological and chronobiological processes in depression. This review aims to provide an overview of the neuroimmunomodulatory processes involved with depression and antidepressant treatments with a special focus on chronobiology, chronotherapeutics and the emerging field of immune-circadian bi-directional crosstalk. Increasing evidence suggests that chronobiological disruption can mediate immune changes in depression, and likewise, immune processes can mediate chronobiological disruption. This may suggest a bi-directional relationship in immune-circadian crosstalk. Furthermore, given the immunomodulatory effects of antidepressants and chronotherapeutics, as well as their associated beneficial effects on circadian disturbance, we-and others-suggest that these therapeutic agents may exert their chronobiotic effects partially via the neuroimmune system. Further research is required to better elucidate the mechanisms of immune involvement in the chronobiology of depression.
    Journal of Neural Transmission 06/2012; 119(10):1147-66. DOI:10.1007/s00702-012-0819-6 · 2.87 Impact Factor
Show more